Teladoc | Diabetes and Weight Management Part 2-Pharmacological Agents for Diabetes and Obesity Infographic

Pharmacological Agents for Diabetes and Obesity Infographic

Pdf Summary

The infographic summarizes recommendations for pharmacologic treatment of diabetes and obesity as per the American Diabetes Association's (ADA) Standards of Care in Diabetes—2023. Key highlights include the efficacy of incretins and weight management for Type 2 Diabetes. These treatments can delay the progression from prediabetes to Type 2 Diabetes, improve glycemic control, reduce the need for glucose-lowering medications, significantly lower A1C and fasting glucose levels, and contribute to sustained diabetes remission for at least two years. Furthermore, obesity management through these pharmacologic agents is shown to aid in meaningful weight loss and reduce obesity-associated health risks.<br /><br />The infographic emphasizes selecting glucose-lowering medications based on their weight effects for individuals with Type 2 Diabetes who are overweight or obese, and suggests minimizing medications for comorbid conditions linked to weight gain. Specific recommendations for treatment options based on Body Mass Index (BMI) are provided, highlighting intensive behavioral counseling, obesity pharmacotherapy, and bariatric surgery for different BMI categories, with a consideration for Asian American individuals' recommended cut points.<br /><br />Obesity pharmacotherapy should be used as an adjunct to nutrition, physical activity, and behavioral counseling, especially for patients with a BMI of 27 kg/m² or higher. Success is typically defined as a 5% weight loss within three months of use. If there's insufficient early response or significant safety or tolerability issues, alternative treatment approaches should be evaluated.<br /><br />A categorized list of glucose-lowering medications is provided, noting their weight loss efficacy: Very High (Semaglutide, Tirzepatide, Dulaglutide, Liraglutide), High (GLP-1 RAs like Exenatide and Lixisenatide), Intermediate (SGLT2 inhibitors), and Neutral (DPP-4 inhibitors, Metformin).<br /><br />Additional resources can be accessed through the ADA for more detailed guidelines and support.

Keywords

diabetes

obesity

ADA Standards of Care 2023

incretins

Type 2 Diabetes

weight management

glucose-lowering medications

BMI

obesity pharmacotherapy

bariatric surgery